孟鲁司特对慢性阻塞性肺疾病急性加重期患者肺功能的影响  

Effect of montel ukast on pulmonary function in patients with acute exacerbation of chronic obstructive pulmonary disease

作　　者：栗春丽 卓致远[2] 李军 LI Chunli;ZHUO Zhiyuan;LI Jun(Graduate School of Bengbu Medical College,Bengbu 233030,China;Department of Respiratory Edicine,Xuzhou Central Hos-pital,Xuzhou 221009,China;Xuzhou Institute of Medical Science,Xuzhou 221006,China)

机构地区：[1]蚌埠医学院研究生院,蚌埠233030 [2]徐州市中心医院呼吸内科,徐州221009 [3]徐州市医学科学研究所,徐州221006

出　　处：《西北药学杂志》2022年第3期171-175,共5页Northwest Pharmaceutical Journal

基　　金：徐州市科技计划项目(编号:KH17042)。

摘　　要：目的探讨孟鲁司特对慢性阻塞性肺疾病急性加重期(AECOPD)患者肺功能、血清D-二聚体(D-D)、纤维蛋白原(FIB)及血清可溶性髓样细胞触发受体-1(sTREM-1)水平的影响。方法选取102例AECOPD患者作为研究对象,并随机分为观察组(51例)和对照组(51例)。对照组采用常规治疗,观察组在对照组治疗的基础上加用孟鲁司特治疗。比较2组治疗前后肺功能[第1秒用力呼气容积(FEV_(1))、用力肺活量(FVC)、FEV_(1)/FVC]、呼吸频率、血气指标[动脉血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))]、健康相关生命质量(HRQoL)量表评分、6 min步行试验、D-D、FIB及sTREM-1水平变化情况,分析2组的临床疗效。结果治疗前,2组各指标比较差异无统计学意义。治疗后,2组FEV_(1)、FVC、FEV_(1)/FVC、PaO_(2)水平和6 min步行试验水平均有所上升,而呼吸频率、PaCO_(2)、HRQoL量表评分、血清D-D、FIB和sTREM-1水平有所下降,且观察组FEV_(1)、FVC、FEV_(1)/FVC、PaO_(2)水平及6 min步行试验水平均高于对照组,呼吸频率、PaCO_(2)、HRQoL量表评分、血清D-D、FIB及sTREM-1水平低于对照组(P<0.05)。观察组和对照组总有效率分别为92.16%、72.55%,差异有统计学意义(P<0.05)。结论孟鲁斯特治疗可显著改善AECOPD患者肺功能、血气指标及D-D、FIB、sTREM-1水平,临床效果显著。Objective To investigate the effects of montel ukast on lung function,serum dimer(D-D),fibrinogen(FIB)and serum soluble myeloid cell trigger receptor-1(sTREM-1)levels in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods A total of 102 AECOPD patients were selected as the research objects and randomly divided into observation group(51 cases)and control group(51 cases).The control group received conventional treatment,and the observa tion group added montelukast treatment on the basis of the control group.The changes of forced breathing volume in the first second(FEV_(1)),forced vital capacity(FVC),FEV/FVC,respiratory rate,oxygen of arterial blood(PaO_(2)),arterial partial pressure of carbondioxide(PaCO_(2)),HRQoL scale,6-minute walk test,D-D,FIB and sTREM-1 levels before and after treatment were compared between the 2 groups,and the clinical efficacy of the 2 groups was analyzed.Results Before treatment,there was no significant difference between the 2 groups in FEV_(1),FVC,FEV_(1)/FVC,respiratory rate,PaO_(2),PaCO_(2),HRQoL scale,6-minute walking test,serum D-D,FIB and sTREM-1 levels(P>0.05).After that,the levels of FEV_(1),FVC,FEV_(1)/FVC,PaO_(2) and the 6-minutes walk test level of the 2 groups increased,while the respiratory rate,PaCO_(2),HRQoL scale,serum D-D,FIB and sTREM-1 levels decreased.Compared with the control group,the observation group had higher levels of FEV_(1),FVC,FEV_(1)/FVC,PaO_(2) and the 6-minute walk test,while the respiratory rate,PaCO_(2),HRQoL scale,serum D-D,FIB and sTREM-1 levels were lower(P<0.05).The total effective rates of the observation group and the control group were 92.16%and 72.55%respectively,and the difference was statistically significant(P<0.05).Conclusion Montelukast treatment can significantly improve the lung function,blood gas indexes,D-D,FIB,and sTREM-1 levels in patients with AECOPD.The clinical effect is significant.

关 键 词：孟鲁司特 慢性阻塞性肺疾病急性加重期(AECOPD) D-二聚体(D-D) 纤维蛋白原(FIB) 血清可溶性髓样细胞触发受体-1(sTREM-1) 

分 类 号：R974[医药卫生—药品]